2025 / 06

Next Paper
DOI: 10.24075/brsmu.2025.074
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

HMGB1 and anti-HMGB1 antibodies in systemic lupus erythematosus and other rheumatic diseases

Melamud MM1 , Ermakov EA1,2 , Tolmacheva AS1 , Sizikov AE1,3 , Klyaus NA4 , Nevinsky GA1 , Buneva VN1,2
About authors

1 Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia

2 Novosibirsk National Research State University, Novosibirsk, Russia

3 Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

4 Almazov National Medical Research Centre, Saint Petersburg, Russia

Correspondence should be addressed: Valentina N. Buneva
prospekt Akademika Lavrentieva, 8, Novosibirsk, 630090, Russia; ur.oib1@avenub

About paper

Funding: this work was supported by the Russian Science Foundation (Grant No. 23-15-00357).

Author contribution: Melamud MM — data analysis, manuscript writing; Ermakov EA — study design, manuscript writing and editing; Tolmacheva AS — experimental work, data analysis; Sizikov AE, Klyaus NA — material collection and preparation, data analysis; Nevinsky GA, Buneva VN — project supervision, editing. The contributions of Melamud MM and Ermakov EA were equal.

Compliance with ethical standards: The study was approved by the Ethics Committee of the Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences (Protocol No. 3 dated June 19, 2023) and was conducted in accordance with the principles of the Declaration of Helsinki. All study participants provided written informed consent.

Received: 2025-10-29 Accepted: 2025-12-06 Published online: 2025-12-14
|
  1. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016; 12: 605–20. Available from: https://doi.org/10.1038/nrrheum.2016.137.
  2. Black RJ, Cross M, Haile LM, Culbreth GT, Steinmetz JD, Hagins H, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023; 5: e594–610. Available from: https://doi.org/10.1016/ S2665-9913(23)00211-4.
  3. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Current Opinion in Rheumatology. 2018; 30: 137–43. Available from: https://doi.org/10.1097/BOR.0000000000000475.
  4. Boel A, López-Medina C, Van Der Heijde DMFM, Van Gaalen FA. Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study. Rheumatology. 2022; 61: 1468–75. Available from: https://doi.org/10.1093/ rheumatology/keab544.
  5. Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis — a systematic review and meta-analysis. Rheumatology. 2024; 63: 3211–20. Available from: https://doi.org/10.1093/rheumatology/keae198.
  6. Lila AM, Lila VA. Social'naya znachimost' i ekonomicheskie posledstviya revmaticheskih zabolevanij. Gigiena i sanitariya. 2017; 96: 387–92. Available from: https://doi.org/10.47470/0016-9900- 2017-96-4-387-392. Russian.
  7. Danieli MG, Antonelli E, Piga MA, Claudi I, Palmeri D, Tonacci A, et al. Alarmins in autoimmune diseases. Autoimmunity Reviews. 2022; 21: 103142. Available from: https://doi.org/10.1016/j.autrev.2022.103142.
  8. Ermakov EA, Tolmacheva AS, Kon’kov VV, Melamud MM, Sizikov AE, Klyaus NA, et al. Plasma high-mobility group nucleosome-binding domain 1 (HMGN1) protein levels in four common rheumatic diseases: A potential biomarker of rheumatoid arthritis. The Egyptian Rheumatologist. 2025; 47: 51–5. Available from: https://doi.org/10.1016/j.ejr.2024.12.003.
  9. Truszewska A, Wirkowska A, Gala K, Truszewski P, Krzemień- Ojak Ł, Perkowska-Ptasińska A, et al. Cell-free DNA profiling in patients with lupus nephritis. Lupus. 2020; 29: 1759–72. Available from: https://doi.org/10.1177/0961203320957717.
  10. Duvvuri B, Lood C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front Immunol. 2019; 10: 502. Available from: https://doi.org/10.3389/fimmu.2019.00502.
  11. Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022; 54: 91–102. Available from: https://doi.org/10.1038/s12276-022-00736-w.
  12. Dong Y, Ming B, Dong L. The Role of HMGB1 in Rheumatic Diseases. Front Immunol. 2022; 13: 815257. Available from: https://doi.org/10.3389/fimmu.2022.815257.
  13. Liu T, Son M, Diamond B. HMGB1 in Systemic Lupus Erythematosus. Front Immunol. 2020; 11: 1057. Available from: https://doi.org/10.3389/fimmu.2020.01057.
  14. Infantino M, Nagy E, Bizzaro N, Fischer K, Bossuyt X, Damoiseaux J. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus. Journal of Translational Autoimmunity. 2022; 5: 100139. Available from: https://doi.org/10.1016/j.jtauto.2021.100139.
  15. Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clinic Rev Allerg Immunol. 2021; 63: 138–51. Available from: https://doi.org/10.1007/s12016-021-08890-1.
  16. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13: R71. Available from: https://doi.org/10.1186/ar3332.
  17. Wirestam L, Schierbeck H, Skogh T, Gunnarsson I, Ottosson L, Erlandsson-Harris H, et al. Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2015; 17: 338. Available from: https://doi.org/10.1186/s13075-015-0856-2.
  18. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch- Puerta M, Patel NB, et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med. 2007; 13: 210–5. Available from: https://doi.org/10.2119/2006–00108.Goldstein.
  19. Wang C, Miao Y, Wu X, Huang Y, Sun M, Zhu Y, et al. Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients. Journal of Immunology Research. 2016; 2016: 1–8. Available from: https://doi.org/10.1155/2016/6537248.
  20. Yildirim D, Baykul M, Edek YC, Gulengul M, Alp GT, Eroglu FS, et al. Could Serum HMGB1 Levels be a Predictor Associated with Psoriatic Arthritis? Biomark Med. 2023; 17: 871–80. Available from: https://doi.org/10.2217/bmm-2023-0490.
  21. Lu M, Yu S, Xu W, Gao B, Xiong S. HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response. Journal of Immunology Research. 2015; 2015: 1–12. Available from: https://doi.org/10.1155/2015/946748.
  22. Tanaka A, Ito T, Kibata K, Inagaki-Katashiba N, Amuro H, Nishizawa T, et al. Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. Lupus. 2019; 28: 1120–7. Available from: https://doi.org/10.1177/0961203319862865.
  23. Lee H-T, Lin C-S, Pan S-C, Chen W-S, Tsai C-Y, Wei Y-H. The Role of Plasma Cell-Free Mitochondrial DNA and Nuclear DNA in Systemic Lupus Erythematosus. Front Biosci (Landmark Ed). 2022; 27: 333. Available from: https://doi.org/10.31083/j.fbl2712333.
  24. Rykova E, Sizikov A, Roggenbuck D, Antonenko O, Bryzgalov L, Morozkin E, et al. Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther. 2017; 19: 85. Available from: https://doi.org/10.1186/s13075-017-1295-z.
  25. Li Z, Lin J, Su Z, Zeng Y, Zhou Y, Li J, et al. Neutrophil Extracellular Traps–Associated RNA Impedes CD4+ Treg Differentiation by TLR7 – IRF7 Axis in Ankylosing Spondylitis. Arthritis & Rheumatology. 2025; 77: 1242–53. Available from: https://doi.org/10.1002/art.43166.
  26. Peng Y, Wu Y, Chen S, Liu Y, Qian H, He Y, et al. Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis. Sci Rep. 2024; 14: 178. Available from: https://doi.org/10.1038/s41598-023-50543-0.